Where Innovation Meets Healthcare
The Clemson University Biomedical Engineering Innovation Campus (CUBEInC) represents the Southeast's premier biomedical innovation ecosystem, where breakthrough technologies become life-changing healthcare solutions.
Spanning 31,000 square feet within Prisma Health Upstate's Patewood Memorial Medical Campus, CUBEInC uniquely bridges the gap between cutting-edge research and clinical application. This state-of-the-art facility brings together world-renowned Clemson University bioengineers, distinguished Prisma Health clinicians, innovative startups, and prestigious research training facilities under one roof. At CUBEInC, we're not just conducting research—we're accelerating the future of medicine through strategic collaboration and commercial translation.
Empowering Tomorrow's Healthcare Leaders
CUBEInC provides far more than premium facilities—we offer a complete ecosystem of support services designed to accelerate your success.
Strategic Advantages
Why Industry Leaders Choose CUBEInC
CUBEInC offers an unmatched combination of strategic advantages for biomedical companies and industry partners. Our collaborative ecosystem provides direct access to clinical environments, world-class research capabilities, and a pipeline of innovative technologies ready for commercialization. Companies benefit from our established relationships with NIH-funded research programs, our proximity to clinical decision-makers, and our proven track record of supporting successful technology transfer. Beyond facilities, we offer a comprehensive support system that includes regulatory guidance, funding opportunities, and access to specialized talent—all designed to accelerate your path from concept to market.
Our Facilities Research LabsShannon Pierce graduated from Clemson University’s College of Nursing fully equipped to work in cardiac care. Utilizing skills acquired during the program enabled her to patent a mobile documentation system and start what is now New Ocean Health System.
“When the company was pre-revenue and doing business as CareCam Innovations, I first became aware of CUBEInC and the ambitious goal to combine academia and commerce in a meaningful and proven manner. I was hooked and wanted to take part. The CUBEInC facilities permitted me to work within a startup budget while enjoying the benefits of a state-of-the-art-environment as well as actively engaged clinicians within close proximity. ”
Shannon PierceFounderNew Ocean Health Solutions
- 31K
SQ FT RESEARCH SPACE
- 15+
PROGRAMS, LABS, COMPANIES
- 2011
FOUNDED IN GREENVILLE
Advancing Health Innovation at Clemson and Beyond
CUBEInC's location within Prisma Health Upstate's Patewood Memorial Medical Campus provides unparalleled strategic advantages for biomedical companies. This positioning offers direct access to clinical environments, patient populations, and medical decision-makers, accelerating research timelines and enhancing the clinical relevance of your innovations.
Improving Drug Efficiencies
Elastrin Therapeutics is a South Carolina biotechnology company that develops novel therapies to reverse cardiovascular disease. Its underlying technology was developed during the last 20 years at Clemson University by Naren Vyavahare in collaboration with Charles Rice, who developed the antibody. The team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. Elastrin aims to target albumin nanoparticles loaded with therapeutic agents directly to the tissue site by utilizing Elastrin’s proprietary anti-elastin monoclonal antibody, created by Vyavahare and co-created by Clemson University biological sciences professor and Elastrin team member, Charles Rice.
Located at CUBEInC, Elastrin was born out of the Hunter Endowed Chair Naren Vyavahare’s research on understanding the reason behind the calcification and stiffening of heart valves and their replacements. What he discovered led to several inventions that are still being used at Elastrin today.
“This targeted delivery promises to improve the efficacy of therapeutic payloads as well as reduce side effects due to otherwise systemic administration. In addition, the nanoparticles result in slower release characteristics that improve the biodistribution of pharmaceuticals at the targeted exposure site.”
Douglas MulhallCo-founderElastrin Therapeutics
Ready to Innovate? →
Join the Southeast's premier biomedical innovation ecosystem and accelerate your path to market.
